RxDoctor Payments Data

Edward Himot, MD

Nephrology · Marietta, GANPI 1639173248

Payments from drug & device makers

$5,475in general payments, 2019–2025

Across 110 payments — averaging $49.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rockwell Medical, Inc.$3K
  • AstraZeneca$332
  • Amgen$307
  • Fresenius USA Marketing, Inc.$292
  • Vifor Pharma, Inc.$270
  • Otsuka America Pharmaceutical, Inc.$253
  • plus $637 from 15 others

What the payments were for

  • Consulting fees$3,38362%
  • Speaking & faculty fees$2004%
  • Food & beverage$1,78133%
  • Education$1102%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,475 in reported general payments places this provider in the 75th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$76,665
Medicare patients
206
Services billed
2,275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide31$95,566
AuryxiaFerric Citrate13$26,803
LokelmaSodium Zirconium Cyclosilicate20$13,371
EliquisApixaban15$8,944
Sevelamer Carbonate16$4,216
Nifedipine ErNifedipine82$3,884
Clonidine27$3,719
Allopurinol241$2,404
SynthroidLevothyroxine Sodium25$2,347
Potassium Chloride47$1,641
Candesartan Cilexetil15$1,576
Levothyroxine Sodium143$1,556
Losartan Potassium78$1,265
Carvedilol132$1,198
Hydralazine Hcl54$1,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$292$95,56631 claims
Akebia Therapeutics IncAuryxia$105$26,80313 claims
AstraZenecaLokelma$332$13,37120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 388 nephrology providers in Georgia.

Other nephrology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →